Trial Profile
Comparative study of intravenous single doses of palonosetron (PALO) with granisetron hydrochloride as a control in patients receiving highly emetogenic chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Oct 2017
Price :
$35
*
At a glance
- Drugs Palonosetron (Primary) ; Granisetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Acronyms PROTECT
- Sponsors Taiho Pharmaceutical
- 11 Oct 2010 Results have been presented at the ESMO (European Society of Medical Oncology) 2010 Congress, according to a Helsinn media release.
- 08 Oct 2010 Results have been presented at the 35th Congress of the European Society for Medical Oncology (ESMO).
- 20 Jan 2010 Palonosetron [Aloxi] was approved in Japan based on the results of this trial, according to a Taiho media release.